Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome

  • Authors:
    • Andreas Roemer
    • Lutz Schwettmann
    • Monika Jung
    • Jan Roigas
    • Glen Kristiansen
    • Dietmar Schnorr
    • Stefan A. Loening
    • Klaus Jung
    • Ralf Lichtinghagen
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/or.11.2.529
  • Pages: 529-536
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

ADAMs (a disintegrin and metalloproteinase) are cell-surface proteins with adhesion and protease activity which play important roles in many biological processes. Little is known about their role in cancer. The aim of the study was to assess the quantitative expression of the ADAMs in human renal cell carcinoma (RCC) and to associate expression levels with clinicopathological data. We investigated the mRNA expression of ADAM-8, -17, -19, -28, ADAM-TS1, and ADAM-TS2 in paired tissue samples from cancerous and non-cancerous parts of the kidneys of 27 patients with RCC who underwent tumour nephrectomy. Measurements were performed by means of the quantitative real-time RT-PCR on a LightCycler instrument. ADAM-8, -17, and -19 were significantly higher expressed (p<0.05 at least) in cancerous compared with the matched non-cancerous tissue in pT1 and ≥pT2 tumours, ADAM-28 and ADAM-TS2 only in pT1 tumours, and ADMA-TS1 was not differently expressed. All ADAMs except ADAM-TS1 showed an increase of expression in the non-cancerous tissue with rising pT stage suggesting an early involvement of ADAMs in the development of RCC. The expression of ADAM-8 was related to a shorter survival of patients and was the best predictor of distant metastases. Our results indicate a potential role for ADAMs in RCC and that the overexpression might be a useful predictive tool.

Related Articles

Journal Cover

February 2004
Volume 11 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Roemer A, Schwettmann L, Jung M, Roigas J, Kristiansen G, Schnorr D, Loening SA, Jung K and Lichtinghagen R: Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep 11: 529-536, 2004
APA
Roemer, A., Schwettmann, L., Jung, M., Roigas, J., Kristiansen, G., Schnorr, D. ... Lichtinghagen, R. (2004). Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncology Reports, 11, 529-536. https://doi.org/10.3892/or.11.2.529
MLA
Roemer, A., Schwettmann, L., Jung, M., Roigas, J., Kristiansen, G., Schnorr, D., Loening, S. A., Jung, K., Lichtinghagen, R."Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome". Oncology Reports 11.2 (2004): 529-536.
Chicago
Roemer, A., Schwettmann, L., Jung, M., Roigas, J., Kristiansen, G., Schnorr, D., Loening, S. A., Jung, K., Lichtinghagen, R."Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome". Oncology Reports 11, no. 2 (2004): 529-536. https://doi.org/10.3892/or.11.2.529